Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BI sees 1H growth, oncology promise, but Spiriva gap looms

This article was originally published in Scrip

Executive Summary

Boehringer Ingelheim saw its prescription medicines business rise 3.5% over the first half of 2013, with COPD product Spiriva (tiotropium) still topping the list as the company's best-selling product. But with the drug due to come off patent in 2016 and nothing coming through the company's respiratory pipeline to fill the revenue gap, analysts do not anticipate that the growth spurt will last, despite the company's flourishing oncology presence.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC022450

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel